After AstraZeneca removed its NSCLC drug osimertinib from the German market following a benefit assessment of...
Up To Date
Latest News
A new analysis comparing the amount of funding invested into stem cell research clearly demonstrates declining...
Investors are once again flocking to back biotechs in Europe. Belgian Life Sciences fund Fund+ has raised...
Part microbe, part machine: cyborg bacteria developed at ETH Zurich could revolutionise the biotechnological...
Nordic Nanovector is expanding its foothold in cancer-fighting ADCs. The Oslo-based biotech has inked a...
Share
